May 17, 2022, 15:42 PM by

Continuing to be a trust-worthy CRO company for drug formulation and development, CD Formulation recently announces the enrichment of its active pharmaceutical ingredient excipient offerings. Now a number of API excipients are readily obtainable at CD Formulation, including Cetrorelix Acetate, Fondaparinux Sodium, Calcitriol, Vitamine D3, Tirofiban Hydrochloride, Eptifibatide, Ferric Ammonium Citrate, Calcipotriol API, Calcium Orotate, Meglumine, Obeticholic Acid, Potassium Magnesium Citrate and Magnesium Oxide.

May 17, 2022, 15:42 PM by

May 17, 2022, 15:42 PM by

May 17, 2022, 15:42 PM by

Biopharma PEG leapts at the opportunity to develop various high purity PEG derivatives used as ADC linkers.

May 17, 2022, 15:42 PM by

Good afternoon, all -- 1upHealth, an intelligent health data platform with over 10,000 clinical and payer endpoints, today unveiled SQL on FHIR to streamline access to and make FHIR healthcare data computable to help organizations discover analytical insights and create compelling visualizations. SQL on FHIR allows healthcare organizations to convert FHIR data into a form that is easily searchable for specifics such as a patient’s observations, vital signs, and smoking status. This new platform is the next phase of 1upHealth’s mission to solve healthcare’s biggest data challenges, including helping organizations convert legacy claims and clinical data into clean, uniform FHIR. If interested in learning more about SQL on FHIR, I am happy to connect you with FHIR expert Joe Gagnon, CEO of 1upHealth, and/or a health plan executive to discuss the following: • Why SQL on FHIR fills the market gap for data conversion and will further aid healthcare organizations to perform at their highest levels • Strategies for organizations to enable FHIR analytics to reduce cost and improve operating models, quality metrics, and outcomes • The urgency to convert FHIR into searchable metrics with interoperability regulations looming and how this will help organizations further track and improve population health and SDoH The full release is included above. Please let me know if you have any questions or requests. Thanks! Anisa

May 17, 2022, 15:42 PM by

May 17, 2022, 15:42 PM by

May 17, 2022, 15:42 PM by

May 17, 2022, 15:42 PM by

May 17, 2022, 15:42 PM by

May 17, 2022, 15:42 PM by

Rapidly expanding pipelines of cell & gene therapies and new vaccines and significant VC fundings are driving the growth of the Biologics CDMO market.

May 17, 2022, 15:42 PM by

With this investment, Biofourmis plans to scale up its virtual care offerings. This includes delivering personalized and predictive in-home care to a growing number of acutely ill patients and expanding its recently announced virtual specialty care services, Biofourmis Care, to those patients with complex chronic conditions. In parallel, Biofourmis plans to fund clinical trials to advance the development of digital therapies that work in conjunction with high-value drugs to improve efficacy, while forming strategic partnerships with companies in the digital health and virtual-first care ecosystems.

May 17, 2022, 15:42 PM by

May 17, 2022, 15:42 PM by

PPMI is designed to identify biological markers and clinical changes associated with Parkinson’s disease risk, onset, and progression.

May 17, 2022, 15:42 PM by

The US Patent and Trademark Office has awarded CTL Amedica Corporation US PAT 11, 291.559, an official patent for the KLIMT™ Expandable Lumbar Interbody Fusion Cage design. The KLIMT™ features proprietary, 3D-printed, expandable technology.

May 17, 2022, 15:42 PM by

The latest version of Genedata Screener features smart workflow automation and fit-for-purpose, big data visualizations that enable fast, functional characterization of tens of thousands of candidate molecules.

May 17, 2022, 15:42 PM by

May 17, 2022, 15:42 PM by

May 17, 2022, 15:42 PM by

May 17, 2022, 01:00 AM by User Not Found

Bio-IT World | Bio-IT World Conference & Expo panelists discussed how diversity, equity, and inclusion are critical to the efficacy of precision medicine. Moderator Kevin Ileka, Bristol Myers Squibb Co., was joined by Adrian Coles, Bristol Myers Squibb Co.; Ari Berman, BioTeam Inc; Lori Lennon, Thinkubator Media; and Victoria Parker, NOBCChE.